Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
1 hedge funds and large institutions have $1.01K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
93% less funds holding
Funds holding: 15 → 1 (-14)
99% less capital invested
Capital invested by funds: $99.4K → $1.01K (-$98.4K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
-$30.2K |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.3K |
| 3 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$8.58K |
| 4 |
6CM
683 Capital Management
New York
|
-$7.86K |
| 5 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$6.9K |
CLDI.WS Hedge Fund Activity: Q4 2024 in Review
1 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q4 2024, worth a combined $1.01K — down 99% from $99.4K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CLDI.WS and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Polar Asset Management Partners, exiting entirely with an estimated $30.2K sold.
- 1 institutional investor held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q4 2024, down from 15 in Q3 2024.
- Funds reported $1.01K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q4 2024, down 99% quarter-over-quarter.
- 0 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q4 2024 and 14 closed out, a net change of -14 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q4 2024 was Polar Asset Management Partners, an estimated $30.2K sold.
Based on aggregated 13F filings for Q4 2024.